Myasthenia Gravis Treatment Market Predicted to Witness Surge in The Near Future

-
Myasthenia Gravis Treatment

Myasthenia Gravis Treatment

Myasthenia gravis (MG) is an autoimmune neuromuscular disease that causes skeletal muscle weakening in the arms and legs. Myasthenia gravis causes double vision, facial paralysis, trouble walking, and eyelid drooping. Testing such as repeated nerve stimulation, blood tests for antibodies, edrophonium tests, computed tomography (CT), and magnetic resonance imaging (MRI) are used to identify this condition (MRI). MG is treated with corticosteroids (azathioprine and cyclosporine) and acetylcholine esterase inhibitors (Edrophonium and Pyridostigmine).

Market Drivers for Myasthenia Gravis Treatment

The Myasthenia Gravis Treatment Market is predicted to rise due to consistent research and development efforts. For example, the US Food and Drug Administration approved Alexion Pharmaceuticals, Inc.'s Soliris, which contains eculizumab as an active ingredient, in October 2017. This medication is used to treat antibody-positive generalized myasthenia gravis, as well as paroxysmal nocturnal hemoglobinuria (PNH), and atypical hemolytic uremic syndrome (aHUS).

Furthermore, the Myasthenia Gravis Treatment Market is predicted to rise as the number of clinical trials for the treatment of myasthenia gravis grows. For example, Novartis AG began a phase II clinical trial of CFZ533 for the treatment of severe myasthenia gravis in December 2017. The major purpose of CFZ533 is to deactivate white blood cells, which modifies the immunological response. As a result, it should aid in the improvement and management of severe myasthenia gravis.

Market Restraints for Myasthenia Gravis Treatment

The Myasthenia Gravis Treatment Market is projected to be hampered by side effects from the medications used to treat the disease. According to a report published in April 2019 by BioNews Services, LLC, high dose combinations of cholinesterase inhibitors (ChEIs) and calcineurin inhibitors (CNIs) like Mestinon and Prograf are to blame for severe muscle cramps in myasthenia gravis patients. As a result, this factor is predicted to stifle the market for myasthenia gravis treatments.

Shire plc, Novartis AG, CSL Behring, Grifols, S.A., Valeant Pharmaceutical International, Inc., Baxter International, Alexion Pharmaceutical Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche AG, Inc., and Avadel Pharmaceutical, PLC are key players in the Myasthenia Gravis Treatment Market.

Comments

Post a Comment

Popular posts from this blog

Security Robot Market to Reach US$ 11.8 Billion by 2022

-
Image
Security Robot Market The Global Security Robot Market is estimated to be valued at US$ 11.8 billion in 2022 and is expected to exhibit a CAGR of 12.87% over the forecast period 2022 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Security robots are rapidly gaining traction due to their ability to enhance security and surveillance in various industries. These robots offer advantages such as round-the-clock monitoring, real-time video monitoring, and quick response to potential threats. The increasing need for advanced security measures to prevent theft, vandalism, and unauthorized access is driving the demand for security robots. These robots are widely used in industries such as retail, healthcare, transportation, and manufacturing to ensure the safety of assets and individuals. The market is expected to witness significant growth due to the rising security concerns and advancements in robotic technologies. Market Key Trends: One ke
Read more

Intravenous Fluid Therapy is the Fastest Growing Segment Fueling the Growth of Intravenous Solutions Market

-
Image
Intravenous Solutions Market The global Intravenous Solutions Market is estimated to be valued at US$ 577,228 bn or Million in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Intravenous solutions are fluids administered through a vein via a needle or catheter. They are often used to provide essential nutrients, medications, or fluids to patients. Common uses include rehydration, correcting electrolyte imbalances, and ensuring nutrition is delivered for patients who cannot eat or absorb nutrients through the digestive system. Market key trends: One of the major trends in the intravenous solutions market is the increasing use of intravenous fluid therapy. Intravenous fluid therapy involves the administration of aqueous solutions containing electrolytes, sugars, and medications through an intravenous catheter. It is widely used for rehydration, maintenance of f
Read more

Global Report on LED Driver Market for the Forecast Period 2023-2030

-
Image
LED Driver Market The LED Driver Market has been growing rapidly over the past few years, driven by the increasing demand for energy-efficient lighting solutions across residential, commercial, and industrial sectors. LED (light-emitting diode) lighting technology has several advantages over traditional lighting solutions such as incandescent and fluorescent lights, including longer lifespan, lower energy consumption, and lower maintenance costs. However, to power and control LED lights, an LED driver is required. The LED Driver Market was valued at USD 7.7 billion in 2020 and is expected to reach USD 10.5 billion by 2025, at a CAGR of 6.4% during the forecast period. LED drivers are electronic devices that regulate the power supply to LED lights. They convert AC voltage from a power source to DC voltage suitable for LEDs, and also provide the necessary current and voltage regulation to ensure proper functioning of the LED lights. LED drivers can be either constant current or constant
Read more